Jacobs Levy Equity Management Inc. Makes New Investment in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Jacobs Levy Equity Management Inc. acquired a new stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,208,069 shares of the company's stock, valued at approximately $1,921,000. Jacobs Levy Equity Management Inc. owned approximately 1.33% of Caribou Biosciences as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Ameriprise Financial Inc. bought a new stake in shares of Caribou Biosciences during the fourth quarter valued at approximately $649,000. Ancora Advisors LLC increased its holdings in shares of Caribou Biosciences by 16.0% during the fourth quarter. Ancora Advisors LLC now owns 58,000 shares of the company's stock valued at $92,000 after acquiring an additional 8,000 shares in the last quarter. Schonfeld Strategic Advisors LLC increased its holdings in shares of Caribou Biosciences by 28.4% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company's stock valued at $3,360,000 after acquiring an additional 467,738 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Caribou Biosciences by 3.4% during the fourth quarter. Northern Trust Corp now owns 714,737 shares of the company's stock valued at $1,136,000 after acquiring an additional 23,531 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Caribou Biosciences during the fourth quarter valued at approximately $288,000. Institutional investors own 77.51% of the company's stock.

Caribou Biosciences Stock Up 2.6%

Shares of NASDAQ:CRBU opened at $0.84 on Friday. The stock has a market cap of $78.11 million, a price-to-earnings ratio of -0.51 and a beta of 2.36. Caribou Biosciences, Inc. has a 12-month low of $0.66 and a 12-month high of $3.72. The business's 50 day moving average is $0.86 and its 200 day moving average is $1.43.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43). Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The business had revenue of $2.35 million for the quarter, compared to analysts' expectations of $1.48 million. As a group, equities research analysts expect that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and set a $3.00 target price (down previously from $9.00) on shares of Caribou Biosciences in a research report on Monday, April 28th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Caribou Biosciences presently has an average rating of "Buy" and a consensus target price of $9.33.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.